The short version of analytical characterisation fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-15 and is reviewed periodically as new material appears.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
is the ion loss by diffusion, convection, attachment, and recombination Dissipation is generally initiated via direct current (DC), radio frequency (RF), or microwave power. Gas ionization efficiency can decrease the power efficiency more than tenfold depending on the carrier plasma and substrate.
== History == Kinohimitsu was established in 1998 and its Healthpad was the first product to be launched by Kino Biotech, which then was certified by US FDA as a medical device. Following the success of Healthpad, Hot Health Pad with Far Infra-Red was launched. In 2001, Kinohimitsu launched Beauty Drink 2500 mg, which was the first collagen drink in Southeast Asia. Kinohimitsu Collagen Diamond 5300 mg is most widely known, and it remains the company's best-selling product with over 1 million bottles sold worldwide. Famous celebrities such as China's Vicki Zhao, Hong Kong's Tavia Yeung and Singapore's Phua Chu Kang and Carrie Wong have also endorsed for Kinohimitsu.
==== Tolerance ==== Tolerance and dependence are risks of chronic benzodiazepine use, and can result in doses within the therapeutic range ceasing to offer meaningful symptomatic relief after prolonged use. Tolerance develops at different rates and to different degrees to the sedative, hypnotic, anticonvulsant, muscle relaxant, and anxiolytic effects of benzodiazepines. A review of benzodiazepine tolerance concluded that it "appears that tolerance develops relatively quickly for the sedative and anticonvulsant actions of benzodiazepines, whereas tolerance to anxiolytic and amnesic effects probably does not develop at all", although the included randomized controlled trial evidence is limited to 22 weeks. A review of clonazepam in the treatment of psychiatric disorders concluded that longitudinal data supports anxiolytic benefit without tolerance during long-term use, including an open-label study finding continued benefit at three years. However, the review concludes that long-term RCT evidence is scant. A study of benzodiazepine sensitivity found that patients treated chronically with alprazolam did not differ from untreated patients in terms of anxiolytic response to diazepam, suggesting a lack of anxiolytic tolerance. However, controversy remains regarding tolerance to anxiolytic effects, with some publications reporting that there is little evidence of continued efficacy beyond 4–6 months or that dependence phenomena are common.
Sources: en.wikipedia.org
=== Hydrostatic skeleton === A hydrostatic skeleton uses hydrostatic pressure generated from muscle contraction against a liquid filled cavity. The liquid filled cavity is commonly referred to as the hydrostatic body. The liquid within the hydrostatic body acts as an incompressible fluid and the body wall of the hydrostatic body provides a passive elastic antagonist to muscle contraction, which in turn generates a force, which in turn creates movement. This structure plays a role in invertebrate support and locomotor systems and is used for the tube feet in starfish and body of worms. A specialized version of the hydrostatic skeleton is a called a muscular hydrostat, which consists of a tightly packed array of three-dimensional muscle fibers surrounding a hydrostatic body. Examples of muscular hydrostats include the arms of octopus and elephant trunks.
Under mild reduction, the naturally occurred (-)-ptaquilosin 11 was obtained. The Yamada's synthesis proceeded in 20 steps with an overall yield of 2.9%. Similarly, the unnatural (+)-enantiomer of ptaquilosin was synthesized from the diastereomer of 2.
Instead strands 3 and 4 will form a hairpin loop further downstream of the ribosome. The hairpin loop formed by strands 3 and 4 is a terminating loop, when the ribosome comes into contact with the loop, it will be “knocked off” the transcript. When the ribosome is removed the His genes will not be translated and histidine will not be produced by the cell.
Woods fled to England that year, where he campaigned against apartheid and further publicised Biko's life and death, writing many newspaper articles about him, as well as a book, Biko (1978). This was made into the 1987 film Cry Freedom by Richard Attenborough, starring Denzel Washington as Biko. Many film critics and Black Consciousness proponents were concerned that the film foregrounded white characters like Woods over Biko himself, but Cry Freedom brought Biko's life and activism to a wider audience. The state censors initially permitted its release in South Africa, but after it began screening in the country's cinemas, copies were confiscated by police on the order of Police Commissioner General Hendrik de Wit, who claimed that it would inflame tensions and endanger public safety. The South African government banned many books about Biko, including those of Arnold and Woods. In 2025, the National Prosecuting Authority announced it would re-open the inquest into Biko's death.
Sources: en.wikipedia.org
A plebiscite on whether the Sanitary Board should have an official or unofficial majority was held in Hong Kong in June 1896. The result of the plebiscite was overwhelmingly for unofficial majority, however no constitutional changes were made for Sanitary Board, though the constitutions of the Executive and Legislative Council were changed as unofficial members were added as a result. The 1896 plebiscite is on record the only referendum conducted by the Hong Kong Government and could be seen as part of the first major debate on the constitutional reform in the crown colony during the 1890s. It was much earlier than the Governor Mark Aitchison Young's Young Plan in the 1940s and 1950s and the rise of the modern pro-democracy camp in the 1980s.
Roberts with a £300 MRC grant in July 1935, and for the next two years Roberts worked with Florey and Maegraith on Florey's lysozyme project. Still, Florey wanted a biochemist on his own staff. He tried to get Hugh Macdonald Sinclair, but Sinclair declined the offer. Norman Pirie asked Florey if he could assume the role, but when Florey approached Sir Frederick Gowland Hopkins, Pirie's boss, Hopkins refused to release Pirie. He tempered this refusal by recommending Ernst Boris Chain, one of many Jewish refugees from Nazi Germany who had found sanctuary in the UK. Chain had recently completed his PhD thesis under Hopkins's supervision. He gratefully accepted Florey's offer of an appointment although it was initially for one year only, and with an annual salary of £200 (equivalent to £12,000 in 2025). In turn, Chain felt that he needed a collaborator, and he had one in mind: Norman Heatley, who was finishing his PhD in Hopkins's department. Heatley was happy to come, and Florey was able to arrange for the MRC to fund the position.
== Metabolism == The half-life of pyridoxine varies according to different sources: one source suggests that the half-life of pyridoxine is up to 20 days, while another source indicates half-life of vitamin B6 is in range of 25 to 33 days. After considering the different sources, it can be concluded that the half-life of pyridoxine is typically measured in several weeks.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.